Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 118.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 249,370 shares of the biopharmaceutical company’s stock after buying an additional 134,993 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Gilead Sciences were worth $20,907,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Atria Investments Inc grew its position in shares of Gilead Sciences by 16.2% in the first quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock valued at $6,557,000 after purchasing an additional 12,507 shares during the last quarter. Cetera Investment Advisers increased its position in Gilead Sciences by 127.6% during the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after buying an additional 119,909 shares in the last quarter. Cetera Advisors LLC raised its holdings in shares of Gilead Sciences by 167.2% in the first quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock worth $6,064,000 after acquiring an additional 51,801 shares during the last quarter. Railway Pension Investments Ltd lifted its position in shares of Gilead Sciences by 0.3% in the first quarter. Railway Pension Investments Ltd now owns 1,563,965 shares of the biopharmaceutical company’s stock valued at $114,560,000 after acquiring an additional 4,800 shares in the last quarter. Finally, IMS Capital Management lifted its position in shares of Gilead Sciences by 34.8% in the first quarter. IMS Capital Management now owns 6,623 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,710 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.2 %

NASDAQ GILD opened at $92.41 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The business has a 50 day moving average price of $88.08 and a two-hundred day moving average price of $77.52. The stock has a market cap of $115.17 billion, a PE ratio of 1,026.78, a P/E/G ratio of 2.81 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 4.37 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,735 shares of company stock worth $5,589,030. 0.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GILD. Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Finally, BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.41.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.